

# A Selective Synthesis of Novel Isoxazolo[2,3-*a*]-quinoxalines and Pyrrolo[1,2-*a*]quinoxalines

Ho Sik Kim [1], Yoshihisa Kurasawa\* and Atsushi Takada

School of Pharmaceutical Sciences, Kitasato University, Shirokane, Minato-ku,  
Tokyo 108, Japan


Received February 3, 1989

The isoxazolo[2,3-*a*]quinoxalines **11a,b** and pyrrolo[1,2-*a*]quinoxalines **12a,b** were selectively synthesized from the 2-substituted 6-chloroquinoxaline 4-oxides **10a,b**. The pyrrolo[1,2-*a*]quinoxalines **12a,b** were clarified to be produced by the ring transformation of the isoxazolo[2,3-*a*]quinoxalines **11a,b**.

*J. Heterocyclic Chem.*, **26**, 871 (1989).

There have been a few papers concerning the 1,3-dipolar cycloaddition reaction of quinoxaline 4-oxide **1a**, 1-oxide **1b** or 1,4-dioxide **1c** with some dipolarophiles. For example, the reaction of **1a** with phenyl isocyanate or benzyne gave an intermediate **2** or **3**, whose ring opening formed the products **4** or **5**, respectively [2]. On the other hand, the reaction of **1b** with dimethyl malonate or *N*-phenylmaleimide afforded the isoxazolo[2,3-*a*]quinoxaline **6a** or **6b**, respectively [3], and the reaction of **1c** with dimethyl acetylenedicarboxylate (DMAD) or *N*-phenylmaleimide provided the diisoxazolo[2,3-*a*:3',2'-*c*]quinoxaline **7a** or **7b**, respectively [3] (Chart 1). However, there has been no paper concerning the synthesis of pyrrolo-

Chart 1



[1,2-*a*]quinoxalines by the 1,3-dipolar cycloaddition reaction of quinoxaline *N*-oxides or by the ring transformation of isoxazolo[2,3-*a*]quinoxalines [4]. In the present investigation, we found that the 2-substituted 6-chloroquinoxaline 4-oxides **10** were selectively transformed into the isoxazolo[2,3-*a*]quinoxalines **11** and pyrrolo[1,2-*a*]quinoxalines **12** (Scheme 1). Moreover, the pyrrolo[1,2-*a*]quinoxalines **12** were found to be produced by the ring transformation of the isoxazolo[2,3-*a*]quinoxalines **11**. This paper describes the above selective synthesis of **11** and **12** together with a postulated mechanism for the ring transformation of **11** into **12**.


The reaction of 2,6-dichloroquinoxaline **8** [5] with *m*-chloroperbenzoic acid gave 2,6-dichloroquinoxaline 4-oxide **9**, whose reaction with piperidine or morpholine afforded 6-chloro-2-(piperidin-1-yl)quinoxaline 4-oxide **10a** or 6-chloro-2-(morpholin-4-yl)quinoxaline 4-oxide **10b**, respectively. The reaction of **10a** or **10b** with an equimolar amount of DMAD provided 8-chloro-2,3-bismethoxycarbonyl-4-(piperidin-1-yl)-3a*H*-isoxazolo[2,3-*a*]quinoxaline **11a** or 8-chloro-2,3-bismethoxycarbonyl-4-(morpholin-4-yl)-3a*H*-isoxazolo[2,3-*a*]quinoxaline **11b**, respectively. On the other hand, the reaction of **10a** or **10b** with 2-fold molar amount of DMAD furnished 8-chloro-1,2,3-trismethoxycarbonyl-4-(piperidin-1-yl)pyrrolo[1,2-*a*]quinoxaline **12a** or 8-chloro-1,2,3-trismethoxycarbonyl-4-(morpholin-4-yl)pyrrolo[1,2-*a*]quinoxaline **12b**, respectively. The reaction of **11a** or **11b** with an equimolar amount of DMAD resulted in ring transformation to give **12a** or **12b**, respectively. A postulated reaction mechanism of the above sequential reactions is shown in Scheme 2.

The structural assignment for the above new compounds **9-12** was based on the analytical and spectral data. The composition of the isoxazolo[2,3-*a*]quinoxalines **11a,b** was checked by the high resolution mass spectral data, since **11a,b** were rather unstable for heating and decomposed while recrystallization.


## EXPERIMENTAL

All melting points were determined on a Ishii melting point apparatus and are uncorrected. The ir spectra (potassium bromide)

Scheme 1



Scheme 2



were recorded with a JASCO IRA-1 spectrophotometer. The nmr spectra were measured in deuteriodimethylsulfoxide with a VXR-300 spectrometer at 300 MHz. Chemical shifts are given in the  $\delta$  scale. The mass spectra (ms) were determined with a JEOL JMS-01S spectrometer. Elemental analyses were performed on a Perkin-Elmer 240B instrument.

#### 2,6-Dichloroquinoxaline 4-Oxide **9**.

A solution of **8** (20 g, 0.10 mole) and *m*-chloroperbenzoic acid (27.2 g, 1.1 equivalents) in chloroform (500 ml) was heated at 60° on a water bath for 7 hours. Removal of the solvent *in vacuo* gave crystals, which were triturated with saturated sodium bicarbonate solution to exclude *m*-chlorobenzoic acid and residual *m*-chloroperbenzoic acid. The crystals were collected by suction filtration and recrystallized from *N,N*-dimethylformamide/ethanol provided pale yellow needles **9** (15.5 g, 72%); mp 176-178°; ir:  $\nu$   $\text{cm}^{-1}$  3060, 1595, 1228; ms:  $m/z$  215 ( $M^+$ ), 217 ( $M^+ + 2$ ); pmr: 8.94 (s, 1H,  $\text{C}_5\text{-H}$ ), 8.35 (d,  $J = 2.5$  Hz, 1H,  $\text{C}_3\text{-H}$ ), 8.07 (d,  $J = 9.0$  Hz, 1H,  $\text{C}_8\text{-H}$ ), 7.83 (dd,  $J = 2.5$  Hz,  $J = 9.0$  Hz, 1H,  $\text{C}_7\text{-H}$ ).

Anal. Calcd. for  $\text{C}_8\text{H}_4\text{Cl}_2\text{N}_2\text{O}$ : C, 44.68; H, 1.87; Cl, 32.98; N, 13.03. Found: C, 44.80; H, 1.89; Cl, 32.95; N, 12.84.

#### 6-Chloro-2-(piperidin-1-yl)quinoxaline 4-Oxide **10a** and 6-Chloro-2-(morpholin-4-yl)quinoxaline 4-Oxide **10b**.

A solution of **9** (10 g, 46.5 mmoles) and piperidine (5.94 g, 69.75 mmoles) or morpholine (6.08 g, 69.75 mmoles) in *N,N*-dimethylformamide (300 ml) was refluxed in an oil bath for 3 hours. Removal of the solvent *in vacuo* gave yellow crystals **10a** or **10b**, which were collected by suction filtration. Recrystallization from *N,N*-dimethylformamide/ethanol afforded yellow needles **10a** (7.24 g, 59%) or **10b** (8.53 g, 69%).

#### Compound **10a**.

This compound had mp 165-166°; ir:  $\nu$   $\text{cm}^{-1}$  3070, 2910, 1572, 1215; ms:  $m/z$  263 ( $M^+$ ), 265 ( $M^+ + 2$ ); pmr: 8.59 (s, 1H,  $\text{C}_5\text{-H}$ ), 8.14 (d,  $J = 2.0$  Hz, 1H,  $\text{C}_3\text{-H}$ ), 7.66-7.55 (m, 2H,  $\text{C}_7\text{-H}$  and  $\text{C}_8\text{-H}$ ), 3.68 (t,  $J = 4.5$  Hz, 4H,  $\text{CH}_2\text{-N-CH}_2$ ), 1.69-1.51 (m, 6H,  $\text{CH}_2\text{-CH}_2\text{-CH}_2$ ).

Anal. Calcd. for  $\text{C}_{13}\text{H}_{14}\text{ClN}_3\text{O}$ : C, 59.21; H, 5.35; Cl, 13.44; N, 15.93. Found: C, 59.30; H, 5.48; Cl, 13.23; N, 15.65.

#### Compound **10b**.

This compound had mp 152-153°; ir:  $\nu$   $\text{cm}^{-1}$  3070, 2940, 1570, 1220; ms:  $m/z$  265 ( $M^+$ ), 277 ( $M^+ + 2$ ); pmr: 8.64 (s, 1H,  $\text{C}_5\text{-H}$ ), 8.17

(d,  $J = 2.0$  Hz, 1H, C<sub>5</sub>-H), 7.71-7.58 (m, 2H, C<sub>7</sub>-H and C<sub>8</sub>-H), 3.75-3.62 (m, 8H, morpholine CH<sub>2</sub>).

*Anal.* Calcd. for C<sub>12</sub>H<sub>12</sub>ClN<sub>3</sub>O<sub>2</sub>: C, 54.25; H, 4.55; Cl, 13.34; N, 15.82. Found: C, 54.24; H, 4.52; Cl, 13.49; N, 15.65.

8-Chloro-2,3-bismethoxycarbonyl-4-(piperidin-1-yl)-3a*H*-isoxazolo[2,3-*a*]quinoxaline **11a**.

A suspension of **10a** (2 g, 7.6 mmoles) and dimethyl acetylenedicarboxylate (1.2 g, 8.36 mmoles) in cyclohexane (200 ml) was refluxed on a boiling water bath for 1 hour to precipitate red needles **11a**, which were collected by suction filtration and then triturated with ethanol (drying: below 80° *in vacuo*) (3.02 g, 98%), mp 224-225°; ir:  $\nu$  cm<sup>-1</sup> 3050, 2920, 1730, 1655, 1595; ms:  $m/z$  405 (M<sup>+</sup>), 407 (M<sup>+</sup> + 2); pmr: 9.35 (s, 1H), 7.90 (s, 2H), 7.70 (s, 1H) (C<sub>3a</sub>-H, C<sub>6</sub>-H, C<sub>7</sub>-H and C<sub>8</sub>-H), 3.85 (s, 4H, CH<sub>2</sub>-N-CH<sub>2</sub>), 3.79 (s, 3H, CH<sub>3</sub>), 3.50 (s, 3H, CH<sub>3</sub>), 1.65 (s, 6H, CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>).

Calcd. for C<sub>19</sub>H<sub>20</sub>ClN<sub>3</sub>O<sub>5</sub>: 405.109 (M<sup>+</sup>), 407.106 (M<sup>+</sup> + 2). Found: 405.110 (M<sup>+</sup>), 407.105 (M<sup>+</sup> + 2).

8-Chloro-2,3-bismethoxycarbonyl-4-(morpholin-4-yl)-3a*H*-isoxazolo[2,3-*a*]quinoxaline **11b**.

A suspension of **10b** (2 g, 7.6 mmoles) and dimethyl acetylenedicarboxylate (1.19 g, 8.36 mmoles) in dioxane (60 ml) was refluxed in an oil bath for 1 hour to precipitate red needles **11b**, which were collected by suction filtration and then triturated with ethanol (drying: below 50° *in vacuo*) (2.97 g, 96%), mp 238-239°; ir:  $\nu$  cm<sup>-1</sup> 3050, 2940, 1730, 1658, 1595; ms:  $m/z$  407 (M<sup>+</sup>), 409 (M<sup>+</sup> + 2); pmr: 9.35 (s, 1H), 7.92 (s, 2H), 7.73 (s, 1H) (C<sub>3a</sub>-H, C<sub>6</sub>-H, C<sub>7</sub>-H and C<sub>8</sub>-H), 3.85 (s, 4H, CH<sub>2</sub>-N-CH<sub>2</sub>), 3.78 (s, 3H, CH<sub>3</sub>), 3.58 (s, 3H, CH<sub>3</sub>), 3.52 (s, 4H, CH<sub>2</sub>-O-CH<sub>2</sub>).

Calcd. for C<sub>18</sub>H<sub>18</sub>ClN<sub>3</sub>O<sub>5</sub>: 407.088 (M<sup>+</sup>), 409.085 (M<sup>+</sup> + 2). Found: 407.085 (M<sup>+</sup>), 409.082 (M<sup>+</sup> + 2).

8-Chloro-1,2,3-trimethoxycarbonyl-4-(piperidin-1-yl)pyrrolo[1,2-*a*]quinoxaline **12a** and 8-Chloro-1,2,3-trimethoxycarbonyl-4-(morpholin-4-yl)pyrrolo[1,2-*a*]quinoxaline **12b**.

A solution of **10a** (2 g, 7.6 mmoles) or **10b** (2 g, 7.6 mmoles) and dimethyl acetylenedicarboxylate (2.35 g, 16.7 mmoles) in dioxane (60 ml) was refluxed in an oil bath for 6 hours. Removal of the solvent *in vacuo* afforded crystals, which were triturated with ethanol/hexane and then collected by suction filtration. Recrystallization from *N,N*-dimethylformamide/water provided colorless needles **12a** (1.06 g, 30%) or **12b** (0.94 g, 27%).

Compound **12a**.

This compound had mp 152-153°; ir:  $\nu$  cm<sup>-1</sup> 3120, 2940, 1730, 1710, 1598; ms:  $m/z$  459 (M<sup>+</sup>), 461 (M<sup>+</sup> + 2); pmr: 7.69 (d,  $J = 2.0$  Hz, 1H, C<sub>6</sub>-H), 7.68 (d,  $J = 9.0$  Hz, 1H, C<sub>6</sub>-H), 7.53 (dd,  $J = 2.0$  Hz,  $J = 9.0$  Hz, 1H, C<sub>7</sub>-H), 4.02 (s, 3H, CH<sub>3</sub>), 3.88 (s, 3H, CH<sub>3</sub>), 3.85 (s, 3H, CH<sub>3</sub>), 3.28 (s, 4H, CH<sub>2</sub>-N-CH<sub>2</sub>), 1.58 (s, 6H, CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>3</sub>).

*Anal.* Calcd. for C<sub>22</sub>H<sub>22</sub>ClN<sub>3</sub>O<sub>6</sub>: C, 57.46; H, 4.82; Cl, 7.71; N, 9.14. Found: C, 57.53; H, 4.85; Cl, 8.01; N, 9.25.

Compound **12b**.

This compound had mp 164-166°; ir:  $\nu$  cm<sup>-1</sup> 3110, 2950, 1725, 1710, 1598; ms:  $m/z$  461 (M<sup>+</sup>), 463 (M<sup>+</sup> + 2); pmr: 7.72 (d,  $J = 9.0$  Hz, 1H, C<sub>6</sub>-H), 7.71 (d,  $J = 2.5$  Hz, 1H, C<sub>6</sub>-H), 7.57 (dd,  $J = 9.0$  Hz,  $J = 2.5$  Hz, 1H, C<sub>7</sub>-H), 4.04 (s, 3H, CH<sub>3</sub>), 3.89 (s, 3H, CH<sub>3</sub>), 3.86 (s, 3H, CH<sub>3</sub>), 3.70 (t,  $J = 4.5$  Hz, 4H, CH<sub>2</sub>-N-CH<sub>2</sub>), 3.29 (t,  $J = 4.5$  Hz, 4H, CH<sub>2</sub>-O-CH<sub>2</sub>).

*Anal.* Calcd. for C<sub>21</sub>H<sub>20</sub>ClN<sub>3</sub>O<sub>7</sub>: C, 54.61; H, 4.37; Cl, 7.68; N, 9.10. Found: C, 54.54; H, 4.39; Cl, 7.68; N, 9.22.

Ring Transformation of **11a,b** into **12a,b**.

A solution of **11a** or **11b** (2 g) and dimethyl acetylenedicarboxylate (0.77 g, 1.1-fold) in dioxane (60 ml) was refluxed in an oil bath for 7 hours. Removal of the solvent *in vacuo* afforded crystals, which were triturated with ethanol and then collected by suction filtration. Recrystallization from *N,N*-dimethylformamide/water gave colorless needles **12a** (0.45 g, 20%) or **12b** (0.75 g, 33%).

Acknowledgement.

We wish to thank Nissan Chemical Industries, Ltd. (Funabashi, Chiba, Japan) for a kind supply of 2,6-dichloroquinoxaline.

#### REFERENCES AND NOTES

- [1] Present address: Department of Chemistry, Teacher's College, Hyosung Women's University, Gyongsan 713-900, Korea.
- [2] J. C. Mason and G. Tennant, *J. Chem. Soc., Chem. Commun.*, 218 (1972).
- [3] M. Ungureanu, I. Druta and I. Zugravescu, *An. Stiint. Univ. "Al. I. Cuza" Iasi, Sect. 1c*, **20**, 29 (1974); *Chem. Abstr.*, **82**, 125351q (1975).
- [4] G. W. H. Cheeseman and R. F. Cookson, "The Chemistry of Heterocyclic Compounds. Condensed Pyrazines", A. Weissberger and E. C. Taylor, eds, John Wiley and Sons, New York, Chichester, Brisbane, Toronto, 1977, pp 598-622, and references cited therein.
- [5] K. Makino, G. Sakata, K. Morimoto and Y. Ochiai, *Heterocycles*, **23**, 2025 (1985).